Faculty
Maria Baggstrom.jpg

Maria Quintos Baggstrom, MD

Associate Professor
Department of Medicine
Oncology Division
Medical Oncology

Clinical Interests

  • Thoracic oncology
  • Clinical trial methodology
  • Medical education

Contact

  • 314-362-5817 (office)
  • 314-362-3895 (fax)
  • 11th Floor Mid-Campus Center (office)
  • Division of Oncology
    Campus Box 8056
    Washington University Medical School
    660 South Euclid Avenue
    St. Louis, MO 63110

Publications

  • Pulsatile erlotinib in EGFR-positive non-small-cell lung cancer patients with leptomeningeal and brain metastases: review of the literature
    How J, Mann J, Laczniak AN, Baggstrom MQ
    Clin Lung Cancer 2017 Jul;18(4):354-363
  • Final results of a phase 3 trial of celecoxib (C) in addition to standard chemotherapy for advanced non-small cell lung cancer with COX- 2 overexpression: CALGB 30801 (Alliance)
    Edelman MJ, Wang X, Hodgson L, Cheney RT, Baggstrom MQ, Sachdev T, Gajra A, Bertino EM, Reckamp KL, Molina J, Schiller J, Mitchell-Edwards K, Friedman P, Ritter J, Milne G, Stinchcombe TE, Hahn O, Vokes EE
    Int J Radiat Oncol Biol Phys 2017 May 1;98(1):220-221
  • Phase III randomized, placebo-controlled, double-blind trial of celecoxib in addition to standard chemotherapy for advanced non-small-cell lung cancer with cyclooxygenase-2 overexpression: CALGB 30801 (Alliance)
    Edelman MJ, Wang X, Hodgson L, Cheney RT, Baggstrom MQ, Thomas SP, Gajra A, Bertino E, Reckamp KL, Molina J, Schiller JH, Mitchell-Richards K, Friedman PN, Ritter J, Milne G, Hahn OM, Stinchcombe TE, Vokes EE
    Alliance for Clinical Trials in Oncology

    J Clin Oncol 2017 Jul 1;35(19):2184-2192
  • Maintenance sunitinib following initial platinum-based combination chemotherapy in advanced-stage IIIB/IV non-small cell lung cancer: a randomized, double-blind, placebo-controlled phase III study-CALGB 30607 (Alliance)
    Baggstrom MQ, Socinski MA, Wang XF, Gu L, Stinchcombe TE, Edelman MJ, Baker S Jr, Feliciano J, Novotny P, Hahn O, Crawford JA, Vokes EE
    J Thorac Oncol 2017 May;12(5):843-849
  • Phase 1b trial of proteasome inhibitor carfilzomib with irinotecan in lung cancer and other irinotecan-sensitive malignancies that have progressed on prior therapy (Onyx IST reference number: CAR-IST-553)
    Arnold SM, Chansky K, Leggas M, Thompson MA, Villano JL, Hamm J, Sanborn RE, Weiss GJ, Chatta G, Baggstrom MQ
    Invest New Drugs 2017 Feb 16; [Epub ahead of print]
  • Consolidation chemotherapy following weekly carboplatin-paclitaxel based chemoradiation for locally advanced non-small cell lung cancer is associated with improved overall and disease-free survival
    Weiner AA, Speirs CK, DeWees TA, Rehman S, Molotievschi A, Velez MA, Mullen D, Fergus S, Trovo M, Baggstrom MQ, Morgensztern D, Govindan R, Waqar SN, Bradley JD, Robinson CG
    Int J Radiat Oncol Biol Phys 2016 Oct 1;96(2S):E441-E442
  • Patterns of care and survival for early versus delayed radiation therapy (RT) in limited-stage small cell lung cancer (LS-SCLC): A review of the National Cancer Data Base
    Robinson CG, Samson P, Bradley JD, Roach MC, DeWees TA, Waqar SN, Baggstrom MQ, Govindan R, Higgins KA, Simone CB 2nd, Grover S, Puri V, Morgensztern D
    Int J Radiat Oncol Biol Phys 2016 Oct 1;96(2S):E436-E437
  • Adjuvant chemotherapy for patients with T2N0M0 NSCLC
    Morgensztern D, Du L, Waqar SN, Patel A, Samson P, Devarakonda S, Gao F, Robinson CG, Bradley J, Baggstrom M, Masood A, Govindan R, Puri V
    J Thorac Oncol 2016 Oct;11(10):1729-35
  • Delayed nausea and vomiting from carboplatin doublet chemotherapy
    Waqar SN, Mann J, Baggstrom MQ, Waqar MA, Chitneni P, Williams K, Gao F, Morgensztern D, Govindan R
    Acta Oncol 2016 Jun;55(6):700-4
  • A phase I trial of temsirolimus and pemetrexed in patients with advanced non-small cell lung cancer
    Waqar SN, Baggstrom MQ, Morgensztern D, Williams K, Rigden C, Govindan R
    Chemotherapy 2016;61(3):144-7
  • Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial
    Soria JC, Felip E, Cobo M, Lu S, Syrigos K, Lee KH, Goker E, Georgoulias V, Li W, Isla D, Guclu SZ, Morabito A, Min YJ, Ardizzoni A, Gadgeel SM, Wang B, Chand VK, Goss GD
    LUX-Lung 8 Investigators (Contributors include: Baggstrom M)

    Lancet Oncol 2015 Aug;16(8):897-907
  • Chemotherapy with or without maintenance sunitinib for untreated extensive-stage small-cell lung cancer: a randomized, double-blind, placebo-controlled phase II study-CALGB 30504 (Alliance)
    Ready NE, Pang HH, Gu L, Otterson GA, Thomas SP, Miller AA, Baggstrom M, Masters GA, Graziano SL, Crawford J, Bogart J, Vokes EE
    J Clin Oncol 2015 May 20;33(15):1660-5
  • Postoperative radiotherapy for pathologic n2 non-small-cell lung cancer treated with adjuvant chemotherapy: a review of the national cancer data base
    Robinson CG, Patel AP, Bradley JD, DeWees T, Waqar SN, Morgensztern D, Baggstrom MQ, Govindan R, Bell JM, Guthrie TJ, Colditz GA, Crabtree TD, Kreisel D, Krupnick AS, Patterson GA, Meyers BF, Puri V
    J Clin Oncol 2015 Mar 10;33(8):870-6
  • Clinical next-generation sequencing in patients with non-small cell lung cancer
    Hagemann IS, Devarakonda S, Lockwood CM, Spencer DH, Guebert K, Bredemeyer AJ, Al-Kateb H, Nguyen TT, Duncavage EJ, Cottrell CE, Kulkarni S, Nagarajan R, Seibert K, Baggstrom M, Waqar SN, Pfeifer JD, Morgensztern D, Govindan R
    Cancer 2015 Feb 15;121(4):631-9
  • A phase I study of pegylated liposomal doxorubicin and temsirolimus in patients with refractory solid malignancies
    Wang-Gillam A, Thakkar N, Lockhart AC, Williams K, Baggstrom M, Naughton M, Suresh R, Ma C, Tan B, Lee W, Jiang X, Mwandoro T, Trull L, Belanger S, Creekmore AN, Gao F, Fracasso PM, Picus J
    Cancer Chemother Pharmacol 2014 Aug;74(2):419-26
  • Lung cancer in older adults
    Frith AE, Baggstrom MQ
    Current Geriatrics Reports 2014 (3):166-74
  • Neoadjuvant docetaxel/estramustine prior to radical prostatectomy or external beam radiotherapy in high risk localized prostate cancer: A phase II trial
    Kim WY, Whang YE, Pruthi RS, Baggstrom MQ, Rathmell WK, Rosenman JG, Wallen EM, Goyal LK, Grigson G, Watkins C, Godley PA
    Urol Oncol 2011 Nov;29(6):608-13
  • A phase II study of AT-101 (gossypol) in chemotherapy-sensitive recurrent extensive-stage small cell lung cancer
    Baggstrom MQ, Qi Y, Koczywas M, Argiris A, Johnson EA, Millward MJ, Murphy SC, Erlichman C, Rudin CM, Govindan R
    J Thorac Oncol 2011 Oct;6(10):1757-1760
  • An open-label, multicenter, three-stage, phase II study of S-1 in combination with cisplatin as first-line therapy for patients with advanced non-small cell lung cancer
    Sandler A, Graham C, Baggstrom M, Herbst R, Zergebel C, Saito K, Jones D
    J Thorac Oncol 2011 Aug;6(8):1400-6
  • Barriers to enrollment in non-small cell lung cancer therapeutic clinical trials
    Baggstrom MQ, Waqar SN, Sezhiyan AK, Gilstrap E, Gao F, Morgensztern D, Govindan R
    J Thorac Oncol 2011 Jan;6(1):98-102
  • Summary of presentations from the 46th Annual Meeting of the American Society of Clinical Oncology: Focus on non-small cell lung cancer (2010)
    Stinchcombe TE, Baggstrom MQ, Somaiah N, Simon GR, Govindan R
    J Thorac Oncol 2011 Jan;6(1):227-232
  • Summary of the proceedings from the 10th Annual Meeting of Molecularly Targeted therapy in Non-small Cell Lung Cancer: Radiotherapy
    Baggstrom MQ, Govindan R
    J Thorac Oncol 2010 Dec;5(12 Suppl 6):S476-7
  • Distinctive characteristics of non-small cell lung cancer (NSCLC) in the young: a surveillance, epidemiology, and end results (SEER) analysis
    Subramanian J, Morgensztern D, Goodgame B, Baggstrom MQ, Gao F, Piccirillo J, Govindan R
    J Thorac Oncol 2010 Jan;5(1):23-8
  • A phase I study of pegylated liposomal doxorubicin and irinotecan in patients with solid tumors
    Morgensztern D*, Baggstrom MQ*, Pillot G, Tan B, Fracasso P, Suresh R, Wildi J, Govindan R (*both authors contributed equally)
    Chemotherapy 2009;55(6):441-5
  • A phase II study of carboplatin, etoposide, and exisulind in patients with extensive small cell lung cancer: CALGB 30104
    Govindan R, Wang X, Baggstrom MQ, Burdette-Radoux S, Hodgson L, Vokes EE, Green MR
    J Thorac Oncol 2009 Feb;4(2):220-6
  • Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a meta-analysis (letter to the editor)
    Stinchcombe TE, Fried DB, Baggstrom MQ, Hensing TA, Socinski MA
    J Thorac Oncol 2008;3(3):320-322
  • A phase I study of bexarotene and rosiglitazone in patients with refractory cancers
    Read WL*, Baggstrom MQ*, Fracasso PM, Govindan R (*both authors contributed equally)
    Chemotherapy 2008 Jun 18;54(3):236-241
  • A phase I study of docetaxel and bexarotene
    Wildi JD, Baggstrom MQ, Suresh R, Read W, Fracasso PM, Govindan R
    Chemotherapy 2008;54(2):125-30
  • The effect of FDG-PET on the stage distribution of non-small cell lung cancer
    Morgensztern D, Goodgame B, Baggstrom MQ, Gao F, Govindan R
    J Thorac Oncol 2008 Feb;3(2):135-9
  • A Phase I trial of weekly docetaxel and topotecan for solid tumors
    Lim WT, Baggstrom MQ, Read W, Fracasso PM, Govindan R
    Acta Oncol 2008;47(2):311-5
  • Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a meta-analysis
    Baggstrom MQ*, Stinchcombe TE*, Fried DB, Poole C, Hensing TA, Socinski MA (*both authors contributed equally)
    J Thorac Oncol 2007 Sep;2(9):845-53
  • Drug delivery and toxicity of adjuvant chemotherapy for non-small cell lung cancer (NSCLC): Washington University experience
    Velcheti V, Viswanathan AK, Baggstrom MQ, Govindan R
    Acta Oncol 2007;46(6):869-70
  • Efficacy of vinorelbine in the second-line setting and beyond in non-small cell lung cancer
    Subramanian J, Velcheti V, Baggstrom MQ, Govindan R
    J Thorac Oncol 2007 Apr;2(4):373
  • A randomized phase II trial comparing every 3-weeks carboplatin/paclitaxel with every 3-weeks carboplatin and weekly paclitaxel in advanced non-small cell lung cancer
    Socinski MA, Ivanova A, Bakri K, Wall J, Baggstrom MQ, Hensing TA, Mears A, Tynan M, Beaumont J, Peterman AH, Niell HB
    Ann Oncol 2006 Jan;17(1):104-9
  • Duration of therapy in advanced, metastatic non-small-cell lung cancer
    Socinski MA, Baggstrom MQ, Hensing TA
    Clin Adv Hematol Oncol 2003 Jan;1(1):33-8